{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T08:36:17Z","timestamp":1775291777807,"version":"3.50.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is limited literature on patterns of everolimus use and subsequent hospitalizations and emergency room (ER) visits in real-world clinical practice. In this study, we describe patterns of everolimus use and hospitalizations and ER visits in a large cohort of patients with breast cancer (BC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>Patients with BC treated with everolimus were identified in the MarketScan database from 2009 to 2016. The pattern of everolimus use and frequency of associated ER visits and hospitalizations during treatment (between the first claim and 30\u2009days after the last claim for everolimus) were identified. Descriptive statistics and regression models were used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 3,556 everolimus users were identified (median age of 60\u2009years; median days of use, 112). The initial prescribed dose was 10 mg in 74.8% of the patients. Compared with the initial dose, 23.5% of patients had a dose change. Forty-six percent of patients were hospitalized or had an ER visit during the treatment with everolimus. Age greater than 71, higher comorbidity score, treatment year prior to 2012, and lower initial dose were found to be significantly associated with ER visit\/hospitalization in the regression models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A significant proportion of patients receiving everolimus had an ER visit or hospitalization during the use of everolimus. These results provide data regarding risks and benefits of treatment with everolimus. These results will be helpful in identifying patients at higher risk of hospitalizations or ER visits and facilitate evidence-based decision making to avoid serious complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Everolimus, a mammalian target of rapamycin inhibitor, is approved in combination with exemestane in patients with hormone receptor\u2013positive tumors previously treated with anastrozole or letrozole. As new drugs become available, it is crucial to understand the adverse events and potential complications associated with the use of such drugs in the general population, outside of the controlled clinical trial setting. This study describes the patterns of everolimus use and adverse events, including hospitalization and emergency room visits, in a large cohort of patients with metastatic breast cancer in routine practice.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0602","type":"journal-article","created":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T06:49:04Z","timestamp":1590994144000},"page":"937-942","source":"Crossref","is-referenced-by-count":8,"title":["Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer"],"prefix":"10.1093","volume":"25","author":[{"given":"Manvi","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Pharmacy Administration, The University of Mississippi, University, Mississippi, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"key":"2021122511250988900_onco13385-bib-0001","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast cancer in the United States","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2021122511250988900_onco13385-bib-0002","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/ajm.AJM_20_17","article-title":"Metastatic breast cancer: Endocrine therapy landscape reshaped","volume":"7","author":"Salkeni","year":"2017","journal-title":"Avicenna J Med."},{"key":"2021122511250988900_onco13385-bib-0003","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1634\/theoncologist.2017-0116","article-title":"Incorporating tumor characteristics to the American Joint Committee on Cancer Breast Cancer Staging System","volume":"22","author":"Chavez-MacGregor","year":"2017","journal-title":"The Oncologist"},{"key":"2021122511250988900_onco13385-bib-0004","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"2021122511250988900_onco13385-bib-0005","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejca.2014.11.021","article-title":"Survival of older patients with metastasised breast cancer lags behind despite evolving treatment strategies\u2013A population-based study","volume":"51","author":"de Glas","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021122511250988900_onco13385-bib-0006","doi-asserted-by":"crossref","first-page":"433","DOI":"10.6004\/jnccn.2017.0044","article-title":"NCCN Guidelines Insights: Breast Cancer, Version 1.2017","volume":"15","author":"Gradishar","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122511250988900_onco13385-bib-0007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/GCO.0000000000000343","article-title":"Breast cancer: Updates and advances in 2016","volume":"29","author":"Giordano","year":"2017","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2021122511250988900_onco13385-bib-0008","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2016.67.1487","article-title":"Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline","volume":"34","author":"Rugo","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511250988900_onco13385-bib-0009","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.2011.39.0708","article-title":"Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study","volume":"30","author":"Bachelot","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122511250988900_onco13385-bib-0010","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12325-013-0060-1","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley","year":"2013","journal-title":"Adv Ther"},{"key":"2021122511250988900_onco13385-bib-0011"},{"key":"2021122511250988900_onco13385-bib-0012"},{"key":"2021122511250988900_onco13385-bib-0013","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2021122511250988900_onco13385-bib-0014","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1080\/14656566.2016.1176148","article-title":"Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+\/HER2- metastatic breast cancer: A retrospective US claims study","volume":"17","author":"Gu\u00e9rin","year":"2016","journal-title":"Expert Opin Pharmacother"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2019-0602","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0602","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0602","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/11\/937\/41920386\/oncolo_25_11_937.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/11\/937\/41920386\/oncolo_25_11_937.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:25:37Z","timestamp":1640431537000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/11\/937\/6443047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":14,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,6,16]]},"published-print":{"date-parts":[[2020,11,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0602","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,6,16]]}}}